MedPath

The Nocturnal Enuresis Alarm Therapy (NEAT) Study

Phase 3
Completed
Conditions
octurnal enuresis
Nocturnal enuresis
Renal and Urogenital - Other renal and urogenital disorders
Registration Number
ACTRN12609000070235
Lead Sponsor
ational Health and Medical Research Council
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
320
Inclusion Criteria

Children >6 years with nocturnal enuresis for at least 3 nights per week for which enuresis alarm therapy is indicated

Exclusion Criteria

Children with organic cause for nocturnal enuresis, defects of central nervous system or significant underlying urological abnormalities or those where alarm therapy is contraindicated.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of patients cured at 4 months measured by a bladder diary[Daily recordings of wet/dry nights collected every 2 weeks for 4 months]
Secondary Outcome Measures
NameTimeMethod
Time to achieve cure measured by bladder diary[Daily recordings of wet/dry nights collected every 2 weeks for 4 months];Proportion of patients relapsed by 12 months. Relapse is defined as greater than 2 nights of wetting/fortnight after achieving cure.[12 months];Response to alarm stimulus will be measured by a bladder diary[Daily recordings of wet/dry nights, waking to void and time to achieve cure will be collected every 2 weeks for 4 months];Adverse outcomes (disturbed sleep) will be assessed daily by a bladder diary kept by the participants.[Daily recordings of any adverse outcomes collected every 2 weeks for 4 months];Overall response to treatment (cure rate) in both arms will be measured by a bladder diary[Daily recordings of wet/dry nights, waking to void, time to achieve cure and any relapse will be collected every 2 weeks for 12 months]
© Copyright 2025. All Rights Reserved by MedPath